New drug combo shows promise in stomach cancer fight
NCT ID NCT07257575
First seen Jan 04, 2026 · Last updated May 26, 2026 · Updated 21 times
Summary
This study tests whether adding the drug serplulimab to standard chemotherapy (FLOT) can help more patients with stage III stomach cancer achieve a complete response before surgery. About 138 participants will receive either the combination or chemo alone, followed by surgery and further treatment. The goal is to see if the combination improves outcomes without increasing side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC CANCER STAGE III are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
No. 106, Zhongshan 2nd Road, Yuexiu District
Guangzhou, Guangdong, 510080, China
Conditions
Explore the condition pages connected to this study.